- Veru Inc. ( NASDAQ: VERU ) fell 6.7% after Culper Research released another short report on the oncology-focused biopharmaceutical company.
- Culper alleged in the report that at baseline, the VERU ( VERU ) study’s placebo group was "markedly sicker than the Sabizabulin Group," according to the report. Culper originally released its first short report on VERU on May 2.
- The latest report comes after Veru ( VERU ) climbed 13% on Wednesday after the company said that Phase 3 results for the anti-viral and anti-inflammatory drug candidate were published in The New England Journal of Medicine .
- VERU didn't immediately respond to Seeking Alpha email request for comment.
- Jefferies on Thursday argued that late-stage results for the VERU's oral COVID therapy sabizabulin could warrant an emergency use nod from the FDA.
For further details see:
Veru drops after Culper Research releases a follow up short report